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ABSTRACT
Since its introduction, total joint arthroplasty
(TJA) has improved the quality of life of patients
with degenerative joint disorders. In the last
decades, a number of conventional and biolog-
ical disease-modifying antirheumatic drugs
have become available for the treatment of
patients with inflammatory rheumatic diseases
(IRD), leading to a reduction in the need to
undergo TJA. However, TJA is still frequently
performed in IRD patients. Both rheumatolo-
gists and orthopedics should be aware that
patients with IRD have a peculiar perioperative
risk profile due to disease-related, patient-re-
lated, and surgery-related risk factors. On the
basis of current evidence, TJA is a safe procedure
for IRD patients as long as an accurate risk
stratification and a multidisciplinary approach
are applied. We here describe the current
strategies for an appropriate surgical manage-
ment of osteoarthritis in IRD patients and the
fascinating opening perspectives that surgeons
and clinicians may expect in the future.
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INTRODUCTION
Orthopedic surgery in patients with inflamma-
tory rheumatic diseases (IRD) historically rep-
resents a challenge for clinicians and orthopedic
surgeons. The prevalence of IRD ranges from
0.05% to 1% in the general population, with
many patients that need a surgical treatment
such as total joint arthroplasty (TJA) because of
articular degeneration [1, 2]. Since the intro-
duction of corticosteroids and non-steroidal
anti-inflammatory drugs (NSAIDs), in the
1950s, it was clear that this approach resulted in
multiple side effects without affecting disease
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progression. Over the last decades, the intro-
duction of conventional synthetic disease-
modifying antirheumatic drugs (csDMARDs)
such as methotrexate and the acknowledge-
ment of the importance of early diagnosis,
prompt treatment, and treat-to-target approach
have led to the improvement of IRD manage-
ment. The development and introduction in
clinical practice of biological DMARDs
(bDMARDs) and, more recently, of targeted
synthetic DMARDs (tsDMARDs) such as tofaci-
tinib have dramatically changed the prognosis
of patients with RA (Fig. 1). The modern treat-
ment of IRD has reduced the need for TJA, but
this procedure is still frequently performed and
a multidisciplinary approach is required to
reduce the risk of adverse events [3]. Surgical
treatment in patients with IRD is often debated
among surgeons because of the fear of infec-
tions, disease flares, and negative surgical out-
comes. In patients with IRD three sets of specific
medical aspects need to be considered when the
articular degeneration requires TJA: the first set
is related to the underlying disease, the second
set is related to therapies, and the third is rela-
ted to surgical technique. Correct management
results in good surgical outcomes and a sub-
stantial decrease in the number of adverse
events. The aim of this communication is to
describe the current strategies for appropriate
management of osteoarthritis in IRD patients
and the fascinating opening perspectives that
surgeons and clinicians may expect for new
drugs and surgical techniques.
ASPECTS RELATED
TO THE UNDERLYING DISEASE
Infections are a dreaded complication of TJA,
resulting in long pharmacological therapies and
worse clinical outcomes. A higher disease
activity has been associated with a higher
probability of developing infections. Despite
the elevated risk of infection, there is currently
no evidence supporting the use of perioperative
protocols different from the general population,
but specific attention is recommended in post-
operative follow-up and wound healing [4–6].
An interesting aspect is the fear of infection
related to previous corticosteroid injections.
Recent comforting data from systematic reviews
Fig. 1 Timeline of the main discoveries and inventions in
orthopedics and rheumatology in the nineteenth and
twentieth century. FDA Food and Drug Administration,
RA rheumatoid arthritis, SLE systemic lupus
erythematosus, TNF tumor necrosis factor. Modiﬁed from
Mocsai et al. (2014) with permission [43]
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confirm that this fear is not actually supported
by evidence [7].
Patients with IRD also have a higher risk of
experiencing cardiovascular events compared to
the general population [8, 9]. The preoperative
assessment of patient-related medical risk fac-
tors should include obesity, malnutrition,
hyperglycemia, uncontrolled diabetes mellitus,
chronic renal failure, smoking, and alcohol
abuse [10]. These factors have proved to con-
tribute to the risk of postoperative infections
following TJA in IRD patients [11]. Conven-
tional risk factors are more common in RA but
do not fully explain the increased cardiovascu-
lar risk, which seems specifically related to
chronic inflammation that may lead, among
other mechanisms, to the reduction of high
density lipoprotein levels and oxidation of low
density lipoproteins with pro-inflammatory
effects [12]. Considering the low risk of life-
threatening bleeding with aspirin, if no major
contraindications are present, the maintenance
of aspirin is feasible and recommended in all
IRD patients who are already in treatment [13].
Recently, a multi-biomarker disease activity
(MBDA) algorithm has been developed com-
bining 12 biomarkers of disease activity among
which are pro-inflammatory cytokines and
other protein biomarkers implicated in the
pathophysiology of joint disease in RA [14].
Higher MBDA scores are associated with a
higher risk of infections, myocardial infarction,
and coronary heart disease [15]; therefore, the
use of MBDA score to stratify patients in a
perioperative setting in the future could replace
the assessment of CRP levels and erythrocyte
sedimentation rate. Similarly, in SLE, a com-
bined soluble mediator score incorporating 52
analytes was studied in order to improve pre-
diction of SLE flares [16].
A higher risk of venous thromboembolism
(VTE) has also been reported as a consequence
of chronic inflammation and endothelial acti-
vation, which increase tissue factor expression
and inhibit endogenous anticoagulants and
fibrinolysis [17]. Major orthopedic procedures,
especially in the lower limb, represent a well-
known risk factor for VTE in the weeks follow-
ing surgery, and a delicate balance between
thrombotic and bleeding events has to be found
in IRD patients [18, 19]. In preoperative car-
diovascular risk stratification of IRD patients,
the presence of antiphospholipid antibodies
(aPL) should also be determined [20]. However,
it is known that a subset of patients with per-
sistent aPL positivity do not ever develop VTE
events in their lifetime. Antibodies directed
against domain I of b2-glycoprotein I (GPI)
highly correlate with thrombosis, supporting
the hypothesis that these antibodies are a clin-
ically relevant subset of anti-b2GPI antibodies
associated with antiphospholipid syndrome
(APS) [21–23]. In the future, these antibodies
may be used as routine biomarkers in perioper-
ative risk stratification. Practical management
strategies to prevent potential perioperative
complications in patients already treated with
anticoagulants should include ensuring correct
hydration of the patient, reducing to a mini-
mum the periods without anticoagulant drugs,
and encouraging postoperative mobilization as
early and as much as tolerated, together with
the use of antithrombotic stockings, if not
contraindicated [6, 24].
Although the role of periodontal disease as a
risk factor for periprosthetic joint infection is
still controversial [25], there is an established
association between periodontal disease and
IRD and future studies should address the
importance of an odontostomatologic evalua-
tion prior to TJA [26]. IRD patients have a
higher risk of depression and other psychologi-
cal diseases due to high tension and low self-
esteem followed by the perceived impact of RA,
fatigue, passive coping, pain, and physical dis-
ability [27]. Considering the relationship
between personality psychology and expected
clinical outcomes, counselling with a psycho-
logical team before surgery is recommended
[28]. Future studies should also evaluate non-
pharmacological management of these patients.
Finally, models for risk stratification will
become more and more accurate and personal-
ized thanks to the most recent technologies
aimed at analyzing large volumes of data sets
regarding patient characteristics and surgical
procedures, with the possibility to share data
among different healthcare institutions [29].
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ASPECTS RELATED TO THERAPIES
The higher risk of infection in the perioperative
period in IRD patients could be associated with
the underlying treatment [24]. Evidence from
RA studies demonstrates that patients on
bDMARDs (both TNF inhibitors and non-TNF
biologics) have an increased risk of serious
infections compared with patients on
csDMARDs, with no differences across
bDMARDs [30]. However, the risk of flares in the
postsurgical period should be carefully evalu-
ated in IRD patients because a disease flare may
require a rise in corticosteroid dosage, thus
increasing the risk of infection. Traditionally, a
suspension of bDMARDs of at least two half-
lives has been recommended so far. However,
half-life may not correspond to the duration of
the immunosuppressant effect as much as the
dosing cycle. Therefore, current guidelines rec-
ommend to withhold biologics on the basis of
the dose interval and tofacitinib, a tsDMARD
targeting Janus kinase/signal transducer and
activator of transcription (JAK/STAT) signaling,
7 days before surgery, respectively [24]. A very
recent case series of Japanese patients with RA
treated with tofacitinib undergoing orthopedic
surgery has been published [31]. No serious
perioperative infections were reported in any
patient during a follow-up of at least 6 months,
thus confirming the safety of the drug.
As a result of the low risk of infection, cur-
rent evidence supports the view that continuing
csDMARDs such as methotrexate, sulfasalazine,
hydroxychloroquine, and azathioprine is a safe
option in RA patients without relevant comor-
bidities [32]. The use of corticosteroids with a
dosage above 15 mg daily is associated with a
higher risk of infection. On the basis of current
evidence, it is advisable to carefully taper the
dose of corticosteroids to below 20 mg pred-
nisone daily and to abandon the practice of
giving ‘‘stress dose steroids’’ because there is no
evidence of a reduced risk of adrenal insuffi-
ciency against a possible increased risk of
infection [24]. The use of NSAIDs should be
evaluated in IRD patients in the perioperative
period, because it is related to an increased
cardiovascular risk and may affect wound and
bone healing in association with corticosteroids
and DMARDs [33]. An effective alternative in
the days after surgery could be the association
of paracetamol with opioids [34].
Inherited differences in drug metabolism
dramatically affect drug response and adverse
effects in each subject. It is tempting to
hypothesize that decreasing costs of genome
sequencing and growing awareness of the asso-
ciation between specific gene polymorphisms
and drug responses will lead in the near future
to evidence-based generated data that can be
applied in perioperative care, in particular for
pain and anesthetic drug management, but also
for antirheumatic drugs [35–37].
ASPECTS RELATED TO SURGERY
TJA in IRD is a challenge for surgeons, whose
responsibility is to choose the most effective
and less invasive technique for these patients
[38]. Many new opportunities are currently
available, such as computer-assisted surgery,
robotic surgery, patient-specific instrumenta-
tions, and fast-track rehabilitation protocols.
Computer-assisted surgery was introduced in
clinical practice at the end of 1990s, and its
clinical application can potentially have a
specific advantage in IRD patients. TJA per-
formed with this technique does not require
intramedullary guides, reducing blood loss and
local trauma [39]. These advantages have been
also described in patient-specific instrumenta-
tions [40]. Robotic surgery represents for many
aspects the future of TJA. It theoretically com-
bines the advantages of computer navigation
with the robotic control of all the surgical steps
regarding the bone cuts. This technique has
been introduced only few years ago and the
preliminary studies report good results, but
actually insufficient literature has been pub-
lished regarding clinical and biomechanical
outcomes [41]. Fast-track rehabilitation proto-
cols represent the state of the art of postopera-
tive care in patients undergoing total joint
replacement, and combined with perioperative
enhanced recovery after surgery (ERAS) proto-
cols can give to patients an early recovery and
better clinical outcomes, especially in the first
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postoperative months as reported by many
studies [42].
CONCLUSIONS
The management of DMARDs and other drugs
in IRD patients undergoing TJA is debated
among orthopedic surgeons and rheumatolo-
gists, thus leading to uncertainty in decision-
making. TJA has a pivotal role in the manage-
ment of IRD patients and quality of life
improvement. Overall, evidence supports the
view that TJA can be performed safely in IRD
patients, as long as a careful risk evaluation is
performed on a multidisciplinary basis.
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